|
KMID : 0370220200640040312
|
|
Yakhak Hoeji
2020 Volume.64 No. 4 p.312 ~ p.318
|
|
|
Analysis of Status and Costs of Medication-Related Osteonecrosis of the Jaw in Korea using the National Health Insurance Service Database
|
|
Kwon Yong-Jin
Park Mi-Hai
|
|
|
Abstract
|
|
|
|
Although Medication-Related Osteonecrosis of the Jaw (MRONJ) does not usually occur, the use of drugs thatmay cause MRONJ is increasing and there is no research reported about its cost and the perception of MRONJ is low inKorea. So here we analyzed the current disease status, such as occurrence and duration, and the cost of treatment ofMRONJ in Korea. It was analyzed by the National Health Insurance Service sample cohort 2.0DB data. Patients wereincluded who diagnosed and treated with ‘Osteonecrosis due to drugs (ICD-10: M87.1)’ or ‘Inflammatory conditions ofjaws (ICD-10: K10.2)’ after the less than three years from the last dose of drugs. A total of 183 MRONJ patients wereidentified. The most frequently administered Bone-Modifying Agents were Alendronate, Risedronate, and Ibandronate. From 2002 to 2015, the proportion of MRONJ in the total number of prescribed patients was between 0.2% and 0.9%. The billing costs for MRONJ per patient was KRW 934,422. The highest cost claim was Surgery of Osteomyelitis ofMandible or Maxilla. The total cost of medical, non-medical and indirect costs was KRW 1,891,808 per patient. Throughthis research, it was found that the cost of treatment of MRONJ was high, and it was possible to analyze the current statusand characteristics of MRONJ in Korea.
|
|
|
KEYWORD
|
|
|
medication-related osteonecrosis of the jaw, osteonecrosis of the jaw, cost analysis, national health insurance service database
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|